title: Multifocal CNS demyelination after octreotide treatment for metastatic meningioma.
authors.affiliation: Department of Neurology, University Hospital Zurich, Switzerland. sebastian.schreglmann@usz.ch
authors.forename: S R
authors.initials: SR
authors.lastname: Schreglmann
authors.forename: I
authors.initials: I
authors.lastname: Jelčić
authors.forename: A B
authors.initials: AB
authors.lastname: Taegtmeyer
authors.forename: M
authors.initials: M
authors.lastname: Linnebank
authors.forename: M
authors.initials: M
authors.lastname: Weller
mesh_terms: D000328:Adult; D018931:Antineoplastic Agents, Hormonal / Q000009:adverse effects* / Q000627:therapeutic use; D002490:Central Nervous System / Q000473:pathology*; D003131:Combined Modality Therapy; D003711:Demyelinating Diseases / Q000134:cerebrospinal fluid / Q000139:chemically induced* / Q000473:pathology; D005074:Evoked Potentials, Visual / Q000502:physiology; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000473:pathology / Q000556:secondary; D008579:Meningioma / Q000188:drug therapy* / Q000556:secondary / Q000601:surgery; D009431:Neural Conduction; D009460:Neurologic Examination; D015282:Octreotide / Q000009:adverse effects* / Q000627:therapeutic use; D017481:Receptors, Somatostatin / Q000378:metabolism
chemical_list: D018931:Antineoplastic Agents, Hormonal; D017481:Receptors, Somatostatin; D015282:Octreotide